Timothy Sullivan is the Chief Financial Officer at Apellis Pharmaceuticals Inc., a biopharmaceutical company focused on developing novel therapeutic approaches for autoimmune and inflammatory diseases. With a robust background in finance and strategic planning within the life sciences industry, Sullivan has been instrumental in steering Apellis towards financial stability and growth. Before joining Apellis, he held significant positions at several notable companies, including serving as the CFO at TESARO, Inc., where he played a pivotal role in the company's successful IPO and eventual acquisition by GlaxoSmithKline. At Apellis, Sullivan oversees all financial aspects of the company, including financial planning and analysis, accounting, and investor relations. His strategic vision has been crucial in managing the company's resources effectively, ensuring that Apellis can continue its research and development efforts while maintaining a strong financial position. Under his leadership, Apellis has successfully navigated the complexities of the biopharmaceutical market, securing funding and partnerships that have propelled the company forward. Sullivan's achievements extend beyond his current role at Apellis. He has a proven track record of driving financial performance and corporate strategy, having led multiple financings and strategic transactions throughout his career. His expertise in the life sciences sector, combined with his strategic acumen, makes him a valuable asset to Apellis as the company continues to innovate and expand its therapeutic offerings.